

Management Change of U.S. Subsidiary Santen Incorporated

May 1, 2002 --- Santen Pharmaceutical Co., Ltd. today announced that the President of its U.S. subsidiary, Santen Incorporated, will be changed as of May 1, 2002 as following:

1. Names and Titles of Newly-assigned and Current Management

	Newly-assigned President	Former President
Name	Dr. Adrienne Graves	Ichiro Otokozawa
Title as of May 1, 2002	Executive President Santen Incorporated	Corporate Officer, Head of Corporate Development & Administration Division Santen Pharmaceutical Co., Ltd.
Former Title	Head of Global Development Santen Incorporated	Corporate Officer, Head of Corporate Development & Administration Division of Santen Pharmaceutical Co., Ltd.; and Executive President of Santen Incorporated

2. Outline of Santen Incorporated

Name: Santen Incorporated
Location: Napa, California, USA
Establishment: January 1993
Equity Ownership: 100% subsidiary of Santen Pharmaceutical Co., Ltd.
Paid-in Capital: US\$ 8,785 thousand
Number of Employees: Approximately 200
Business: Development, manufacture and sale of prescription pharmaceuticals
Main Products: Quixin (anti-infective ophthalmic solution), Betimol (anti-glaucoma ophthalmic solution) and Alamast (anti-allergic ophthalmic solution)